 Home > Active Ingredient News > Antitumor Therapy > BeiGene initiates a phase 1 clinical trial of HPK1 inhibitor...

BeiGene initiates a phase 1 clinical trial of HPK1 inhibitor...

 Last Update: 2021-03-25
 Source: Internet
 Author: User

Tags

presumptive drug test

company press release

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Source: Guanlan Pharmaceutical

Recently, BeiGene announced that a phase 1 clinical trial of its in-development hematopoietic stem cell kinase 1 (HPK1) inhibitor BGB-15025 has completed its first patient administration.

HPK1 is a key negative feedback regulator of T cell receptor (TCR) signaling and is believed to play a key role in the anti-tumor immune response.

The press release shows that the first phase 1 clinical trial in humans launched this time aims to evaluate the safety, tolerability, and pharmacokinetics of BGB-15025 as a single agent or in combination with Bezan in patients with advanced solid tumors.

Note: The original text has been deleted

▽ attention [drug Mingkang Germany ] micro-channel public number

[Medical attention Mingkang Germany ] ] micro-channel public number

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

BeiGene initiates a phase 1 clinical trial of HPK1 inhibitor

03-21

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

BeiGene initiates a phase 1 clinical trial of HPK1 inhibitor...

Related Articles

BeiGene initiates a phase 1 clinical trial of HPK1 inhibitor